Literature DB >> 17109502

Alterations of biliary biochemical constituents and cytokines in infantile hepatitis syndrome.

Yan Ding1, Lei Zhao, Hong Mei, Zhi-Hua Huang, Shu-Ling Zhang.   

Abstract

AIM: To investigate the biliary biochemical constituents and cytokines in infantile hepatitis syndrome (IHS).
METHODS: From 42 IHS subjects and 21 controls, serum and biliary biochemical constituents, including total bilirubin (TBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (gamma-GT), total bile acid (TBA), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) both in bile and serum, were assayed. The subjects with IHS were divided into a cholestasis group (n = 21) and a hepatitis group (n = 21).
RESULTS: In the cholestasis group, serum TBIL, DBIL, ALT, gamma-GT, TBA, IL-6 and TNF-alpha levels were higher than those in the control (P < 0.01); and also the biliary TBIL, DBIL, gamma-GT and TBA levels were lower than those in the control, whereas biliary IL-6 and TNF-alpha levels were higher than those in the control (P < 0.01). In the cholestasis group, serum IL-6 and TNF-alpha levels were lower than those in bile (P < 0.01). In the hepatitis group, serum DBIL, ALT, gamma-GT, TBA, IL-6 and TNF-alpha levels were higher than those in the control (P < 0.01 or 140.57 +/- 70.32 vs 79.06 +/- 35.25, P < 0.05), while biliary TBIL, DBIL, gamma-GT and TBA levels were lower than those in the control (P < 0.01), and biliary IL-6 and TNF-alpha levels were higher than those in the control (P < 0.01). In the hepatitis group, serum IL-6 and TNF-alpha levels were also lower than those in bile (P < 0.01). Serum TBIL, DBIL, gamma-GT, IL-6 and TNF-alpha levels in the cholestasis group were higher than those in the hepatitis group, while biliary IL-6 and TNF-alpha levels in the cholestasis group were higher than those in the hepatitis group. Biliary IL-6 and TNF-alpha were found to be more significantly increased than serum IL-6 and TNF-alpha in IHS (P < 0.01). The biliary IL-6 and TNF-alpha levels were positively correlated with serum DBIL, TBA and gamma-GT levels in IHS subjects.
CONCLUSION: Biliary biochemical constituents alter in coincidence with pathological changes in hepatocellular injury. Cholestasis is more serious in IHS patients of cholestasis subtype. Assay of biliary IL-6 and TNF-alpha levels can be specific and sensitive to determine the inflammatory status of impaired liver in IHS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109502      PMCID: PMC4087351          DOI: 10.3748/wjg.v12.i43.7038

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  6 in total

1.  [Changes and significance of tumor necrosis factor-alpha and interleukin-6 level in plasma and bile during the formation of acute intrahepatic cholestasis in New Zealand white rabbits].

Authors:  Zhi-hua Huang; Xin Huang; Yan Li
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-05

2.  Biliary interleukin-6 and tumor necrosis factor-alpha in patients undergoing endoscopic retrograde cholangiopancreatography.

Authors:  H R Rosen; P J Winkle; B J Kendall; D L Diehl
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

3.  Effect of tumor necrosis factor alpha on intrahepatic bile duct epithelial cell of rat liver.

Authors:  Y Mano; M Ishii; H Okamoto; T Igarashi; K Kobayashi; T Toyota
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

4.  Differential developmental regulation of rat liver canalicular membrane transporters Bsep and Mrp2.

Authors:  Gitit Tomer; Meenakshisundaram Ananthanarayanan; Alexander Weymann; Natarajan Balasubramanian; Frederick J Suchy
Journal:  Pediatr Res       Date:  2003-02       Impact factor: 3.756

Review 5.  Neonatal cholestasis.

Authors:  P J McKiernan
Journal:  Semin Neonatol       Date:  2002-04

6.  [Dynamic examination of duodenal fluid in the differential diagnosis of infantile cholestatic jaundice].

Authors:  Zhi-hua Huang; Yong-sui Dong
Journal:  Zhonghua Er Ke Za Zhi       Date:  2004-01
  6 in total
  8 in total

1.  Evaluation of the protective effect of Rhei Radix et Rhizoma against α-naphthylisothiocyanate induced liver injury based on metabolic profile of bile acids.

Authors:  Fan Yang; Ying Xu; Aizhen Xiong; Yugi He; Li Yang; Yu-Jui Yvonne Wan; Zhengtao Wang
Journal:  J Ethnopharmacol       Date:  2012-10-08       Impact factor: 4.360

2.  Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo.

Authors:  Fan Yang; Yao Wang; Gang Li; Juan Xue; Zhi-Lin Chen; Feng Jin; Lei Luo; Xuan Zhou; Qian Ma; Xin Cai; Hua-Rong Li; Lei Zhao
Journal:  Br J Pharmacol       Date:  2018-01-25       Impact factor: 8.739

Review 3.  Liver involvement in systemic infection.

Authors:  Masami Minemura; Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Hepatol       Date:  2014-09-27

4.  Construction of PIK3C3 Transgenic Pig and Its Pathogenesis of Liver Damage.

Authors:  Jing Wang; Sami Ullah Khan; Pan Cao; Xi Chen; Fengchong Wang; Di Zou; Honghui Li; Heng Zhao; Kaixiang Xu; Deling Jiao; Chang Yang; Feiyan Zhu; Yaxuan Zhang; Yanhua Su; Wenmin Cheng; Baoyu Jia; Yubo Qing; Muhammad Ameen Jamal; Hong-Ye Zhao; Hong-Jiang Wei
Journal:  Life (Basel)       Date:  2022-04-24

Review 5.  Liver in systemic disease.

Authors:  Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

Review 6.  Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications.

Authors:  Inaam A Nakchbandi
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

7.  Establishment of a new acute-on-chronic liver failure model.

Authors:  Fangfang Li; Luyang Miao; Hua Sun; Yuyang Zhang; Xiuqi Bao; Dan Zhang
Journal:  Acta Pharm Sin B       Date:  2016-10-31       Impact factor: 11.413

Review 8.  Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases.

Authors:  Ting Liu; Yu Zhou; Kwang Suk Ko; Heping Yang
Journal:  Mediators Inflamm       Date:  2015-10-05       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.